SGLT-2抑制剂对心血管保护作用的研究概况

摘要/Abstract

摘要： 钠-葡萄糖协同转运蛋白-2（SGLT-2）抑制剂是一类新型的治疗2型糖尿病的药物，降糖效果好，不良反应发生率低，近年来有研究发现，除降糖作用以外，SGLT-2抑制剂还具有心血管保护作用。本文将从对心血管危险因素的影响、对肾脏的影响、降低尿酸、减少炎症、改善心脏能量代谢以及预防心脏重构等方面概述SGLT-2抑制剂的心血管保护作用。

关键词: font-size:medium, ">SGLT-2抑制剂；心血管保护；糖尿病

Abstract: Sodium-glucosecotransporter-2 (SGLT-2) inhibitors are a new class of drugs in the treatment of type 2 diabetes. Hypoglycemic effect was well， the incidence of adverse reactions was low. In recent years， studies have found that in addition to hypoglycemic effects， SGLT-2 inhibitors also have cardiovascular protective effects. This paper will summarize the cardiovascular protective effects of SGLT-2 inhibitors from the aspects of effects on cardiovascular risk factors and kidneys， lowering blood pressure， lowering uric acid， reducing inflammation， improving cardiac energy metabolism， and preventing cardiac remodeling.

Key words: SGLT-2 inhibitors, Cardiovascular protection, Diabetes

中图分类号:

盖克克, 贾琼, 王真真, 王滨. SGLT-2抑制剂对心血管保护作用的研究概况[J]. 中国药物评价, 2022, 39(4): 342-344.

GAI Ke-Ke, JIA Qiong, WANG Zhen-zhen, WANG Bin. Research Progress on Cardiovascular Protection of SGLT-2 Inhibitors[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2022, 39(4): 342-344.

参考文献

[1]Saeedi P， Petersohn I， Salpea P， et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas[J]. Diabetes research and clinical practice， 2019， 157: 107843.
     [2]中国2型糖尿病防治指南（2020年版）（上）[J].中国实用内科杂志， 2021， 41(08): 668-695.
     [3]De Rosa S， Arcidiacono B， Chiefari E， et al. Type 2 diabetes mellitus and cardiovascular disease: genetic and epigenetic links[J]. Frontiers in endocrinology， 2018， 9: 2.
     [4]盖克克. 在二甲双胍治疗基础上DPP-4抑制剂与其它类型降糖药物的疗效和安全性Meta分析[D].天津医科大学，2017.
     [5]Zelniker TA， Wiviott SD， Raz I， et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus: systematic review and meta-analysis of cardiovascular outcomes trials[J]. Circulation， 2019， 139(17): 2022-2031.
     [6]Kario K， Okada K， Kato M， et al. 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized， placebo-controlled SACRA study[J]. Circulation， 2018， 139(18): 2089.
     [7]Laffel L. Ketone bodies: a review of physiology， pathophysiology and application of monitoring to diabetes[J]. Diabetes/metabolism research and reviews， 1999， 15(6): 412-426.
     [8]Zinman B， Wanner C， Lachin J M， et al. Empagliflozin， cardiovascular outcomes， and mortality in type 2 diabetes[J]. New England Journal of Medicine， 2015， 373(22): 2117-2128.
     [9]Leiter LA， Yoon KH， Arias P， et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized， double-blind， phase 3 study[J]. Diabetes care， 2015， 38(3): 355-364.
     [10]Rosenstock J， Aggarwal N， Polidori D， et al. Dose-ranging effects of canagliflozin， a sodium-glucose cotransporter 2 inhibitor， as add-on to metformin in subjects with type 2 diabetes[J]. Diabetes care， 2012， 35(6): 1232-1238.
     [11]Sánchez-García A， Simental-Mendía M， Millán-Alanís JM， et al. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials[J]. Pharmacological Research， 2020， 160: 105068.
     [12]Szekeres Z， Toth K， Szabados E. The effects of SGLT2 inhibitors on lipid metabolism[J]. Metabolites， 2021， 11(2): 87.
     [13]Hayashi T， Fukui T， Nakanishi N， et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin[J]. Cardiovascular diabetology， 2017， 16(1): 1-13.
     [14]Persson F， Rossing P， Vart P， et al. Efficacy and safety of dapagliflozin by baseline glycemic status: A prespecified analysis from the DAPA-CKD trial[J]. Diabetes care， 2021， 44(8): 1894-1897.
     [15]Fioretto P， Zambon A， Rossato M， et al. SGLT2 inhibitors and the diabetic kidney[J]. Diabetes Care， 2016， 39(Supplement_2): S165-S171.
     [16]Alderman MH. Uric acid and cardiovascular risk[J]. Current opinion in pharmacology， 2002， 2(2): 126-130.
     [17]Hu X， Yang Y， Hu X， et al. Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis[J]. Diabetes， Obesity and Metabolism， 2022， 24(2): 228-238.
     [18]Yuan T， Liu S， Dong Y， et al. Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes: a prospective pilot trial[J]. Diabetology & Metabolic Syndrome， 2020， 12(1): 1-9.
     [19]Burgos-Morón E， Abad-Jiménez Z， Maraón AM， et al. Relationship Between Oxidative Stress， ER Stress， and Inflammation in Type 2 Diabetes: The Battle Continues[J]. Clin Med， 2019 Sep 4;8(9):1385.
     [20]Iannantuoni F， M de Maraon A， Diaz-Morales N， et al. The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes[J]. Journal of clinical medicine， 2019， 8(11): 1814.
     [21]Santos-Gallego CG， Requena-Ibanez JA， San Antonio R， et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics[J]. Journal of the American College of Cardiology， 2019， 73(15): 1931-1944.
     [22]Ferrannini E， Baldi S， Frascerra S， et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes[J]. Diabetes， 2016， 65(5): 1190-1195.
     [23]Lopaschuk GD， Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review[J]. Basic to Translational Science， 2020， 5(6): 632-644.
     [24]Verma S， Mazer CD， Yan AT， et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial[J]. Circulation， 2019， 140(21): 1693-1702.